Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: A CALGB (9011) coordinated intergroup study

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 1, 2002, Pages 37-45

  Martell, Robert E ^a,b,i,j   Peterson, Bercedis L ^b,i,j   Cohen, Harvey ^a,b,i,j   Petros, William P ^b,i,j   Rai, Kanti R ^b,c,i,j   Morrison, Vicki A ^b,d,i,j   Elias, Laurence ^b,f,i,j   Shepherd, Lois ^b,g,i,j   Hines, John ^b,h,i,j   Larson, Richard A ^b,e,i,j   Schiffer, Charles A ^b,e,i,j   Hurwitz, Herbert I ^b,i,j  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Cancer and Leukemia Group B   (United States)

^f Southwest Oncology Group   (United States)

^g Institut national du cancer du Canada   (Canada)

^h Eastern Cooperative Oncology Group   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j WAYNE STATE UNIVERSITY   (United States)

more..

Author keywords

Aging; Chronic lymphocytic leukemia; Drug toxicity; Fludarabine; Kidney function tests

Indexed keywords

CREATININE; FLUDARABINE;

ADULT; AGE; AGED; ARTICLE; BLOOD TOXICITY; BODY MASS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CYTOTOXICITY; EVALUATION; FEMALE; HUMAN; INFECTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PREDICTION; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BODY MASS INDEX; CREATININE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC TESTS; HUMANS; KIDNEY FUNCTION TESTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPHILS; VIDARABINE;

EID: 0036308568     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0443-5     Document Type: Article

References (59)

1. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age
2. Fludarabine in chronic leukaemia
3. Pharmacology of cancer chemotherapy in the older person
4. Clinical trials and drug toxicity in the elderly
5. Guide to drug dosage in renal failure
6. Renal functional reserve in elderly patients
7. Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5′-monophosphate (NSC 312887), a new purine antimetabolite
8. Exclusion of elderly people from clinical research: A descriptive study of published reports
9. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
10. Fludarabine phosphate: A synthetic purine antimetabolite with significant activity against lymphoid malignancies
11. Prediction of creatinine clearance from serum creatinine
12. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas
13. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine
14. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: A report from the Children's Cancer Group
15. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience
16. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: A Southwest Oncology Group study
17. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis
18. Renal functional reserve in healthy elderly subjects
19. Cyclophosphamide methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance
20. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: An Illinois Cancer Center study
21. T-cell subset counts and serum immunoglobulin concentrations in patients with chronic renal failure at the Kenyatta National Hospital
22. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis
23. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity
24. Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia
25. Age-related patterns of care: Evidence against ageism in the treatment of early-stage breast cancer
26. Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications
27. Pharmacokinetic study of fludarabine phosphate (NSC 312887)
28. Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia
29. Nonparametric estimation from incomplete observations
30. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia
31. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia
32. Clinical pharmacokinetic considerations in the elderly. An update
33. Development of a fludarabine phosphate (FAMP) dosing formula in patients with renal insufficiency based on a pharmacokinetic (PK) study in patients with and without renal impairment
34. Assessment of renal function in the old. Special considerations
35. Longitudinal studies on the rate of decline in renal function with age
36. Age-related declines in hematopoietic reserve capacity
37. Measured versus estimated creatinine clearance in a high-functioning elderly sample: MacArthur Foundation Study of Successful Aging
38. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate
39. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma
40. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: The Spanish Group experience
41. The impact of therapy with chlorambucil, fludarabine, or chlorambucil + fludarabine on infections in patients with chronic lymphocytic leukemia (CLL): An intergroup study (CALGB 9011)
42. Serum creatinine as an index of renal function: New insights into old concepts
43. A predictive model for aggressive non-Hodgkin's lymphoma
44. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia
45. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
46. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial
47. Chronic lymphocytic leukemia
48. The newer purine analogs. Significant therapeutic advance in the management of lymphoid malignancies
49. Influence of age on the treatment of limited-stage small-cell lung cancer
50. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte
51. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy
52. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: Five-year follow-up report
53. The approach to the elderly patient with acute myeloid leukemia
54. Non-Hodgkin's lymphomas in 137 patients aged 70 years or older: A retrospective European Organization for Research and Treatment of Cancer Lymphoma Group study
55. Representation of older patients in cancer treatment trials
56. Mixed-type autoimmune hemolytic anemia following fludarabine treatment in a patient with chronic lymphocytic leukemia/small cell lymphoma
57. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma
58. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia
59. Cancer in older persons. Magnitude of the problem - How do we apply what we know?